CN111803617A - Microcapsule-loaded stem cell system and preparation method thereof - Google Patents
Microcapsule-loaded stem cell system and preparation method thereof Download PDFInfo
- Publication number
- CN111803617A CN111803617A CN202010685869.XA CN202010685869A CN111803617A CN 111803617 A CN111803617 A CN 111803617A CN 202010685869 A CN202010685869 A CN 202010685869A CN 111803617 A CN111803617 A CN 111803617A
- Authority
- CN
- China
- Prior art keywords
- stem cells
- stem cell
- microcapsules
- cell system
- incubation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 32
- 239000003094 microcapsule Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 230000012202 endocytosis Effects 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- 238000011534 incubation Methods 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 210000001178 neural stem cell Anatomy 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a stem cell system internally loaded with microcapsules, which takes stem cells as a cell carrier to load the microcapsules, wherein the loading mode is a cell endocytosis method; wherein the microcapsule contains polypeptide substance. The method has the advantages of simple and stable operation, deepening essence, gradual process and safety guarantee.
Description
Technical Field
The invention belongs to the technical field of biomedicine and nanomedicine, and particularly relates to a stem cell system internally loaded with microcapsules and a preparation method thereof.
Background
Neural stem cells (neural stem cells) refer to a cell population that exists in the nervous system, has the potential to differentiate into neurons, astrocytes and oligodendrocytes, and thus is capable of generating a large amount of brain cell tissue, and is capable of self-renewal, and sufficiently providing a large amount of brain tissue cells.
Is a type of mother cell with division potential and self-renewal ability, which can generate various types of cells of nervous tissues by unequal division modes. It is emphasized that different neural stem cell types produce different types and distributions of daughter cells in all neural tissues such as the cerebrospinal fluid.
The active peptide mainly controls the growth, development, immunoregulation and metabolism of a human body, the active peptide is in a balanced state in the human body, if the active peptide is reduced, the function of the human body is changed significantly, for children, the growth and development of the children become slow, even stop, a dwarfism is formed after a long time, for adults or old people, after the active peptide is lacked, the immunity of the children is reduced, the metabolism is disordered, the endocrine disorder is caused, and various diseases such as insomnia, emaciation or edema are caused. Because the active peptide also acts on the nervous system, the human body can become sluggish in action, and the head and the brain can not be clever any more, and more importantly, the active peptide is reduced, so that all parts of the human body can be gradually aged, and various diseases can be caused.
Disclosure of Invention
The invention mainly aims to overcome the defects of the prior art and provide a stem cell system internally loaded with microcapsules and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a stem cell system internally loaded with microcapsules takes stem cells as a cell carrier, and the stem cells are loaded in a way of endocytosis; wherein the microcapsule contains polypeptide substance.
Preferably, the stem cell is a mesenchymal stem cell or a neural stem cell.
Preferably, an endocytosis method is used, comprising the steps of: CO-incubating the stem cells and the microcapsules in a stem cell culture solution, wherein the number of the stem cells is 105-108, the incubation time is 1-96 h, the drug concentration is 1-100 mu g/mL, the incubation temperature is 30-45 ℃, and other incubation conditions are that the stem cells and the microcapsules contain 1-10% of CO2。
Preferably, the incubation time is 12h, and the drug concentration is50 μ g/mL, incubation temperature 37 ℃ and other incubation conditions were 5% CO2。
The method has the advantages of simple and stable operation, deepening essence, gradual process and safety guarantee.
Detailed Description
The present invention will be further described below, and it should be noted that the following examples are provided to illustrate the detailed embodiments and specific procedures based on the technical solution, but the scope of the present invention is not limited to the examples.
The invention relates to a stem cell system internally loaded with microcapsules, which takes stem cells as a cell carrier and loads the microcapsules in a cell endocytosis method; wherein the microcapsule contains polypeptide substance.
Preferably, the stem cell is a mesenchymal stem cell or a neural stem cell.
Preferably, an endocytosis method is used, comprising the steps of: CO-incubating the stem cells and the microcapsules in a stem cell culture solution, wherein the number of the stem cells is 105-108, the incubation time is 1-96 h, the drug concentration is 1-100 mu g/mL, the incubation temperature is 30-45 ℃, and other incubation conditions are that the stem cells and the microcapsules contain 1-10% of CO2。
Preferably, the incubation time is 12h, the drug concentration is 50. mu.g/mL, the incubation temperature is 37 ℃, and other incubation conditions are 5% CO2。
Various corresponding changes and modifications can be made by those skilled in the art based on the above technical solutions and concepts, and all such changes and modifications should be included in the protection scope of the present invention.
Claims (4)
1. A stem cell system internally loaded with microcapsules is characterized in that stem cells are used as a cell carrier in the system, and the system is loaded with the microcapsules in a manner of endocytosis; wherein the microcapsule contains polypeptide substance.
2. The microencapsulated stem cell system according to claim 1 wherein the stem cells are mesenchymal stem cells or neural stem cells.
3. A method for preparing the microencapsulated stem cell system according to claim 1, wherein the endocytosis method is used, which comprises the steps of: CO-incubating the stem cells and the microcapsules in a stem cell culture solution, wherein the number of the stem cells is 105-108, the incubation time is 1-96 h, the drug concentration is 1-100 mu g/mL, the incubation temperature is 30-45 ℃, and other incubation conditions are that the stem cells and the microcapsules contain 1-10% of CO2。
4. The method according to claim 7, wherein the number of stem cells is 106-107, the incubation time is 12h, the drug concentration is 50 μ g/mL, the incubation temperature is 37 ℃, and other incubation conditions are 5% CO2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010685869.XA CN111803617A (en) | 2020-07-16 | 2020-07-16 | Microcapsule-loaded stem cell system and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010685869.XA CN111803617A (en) | 2020-07-16 | 2020-07-16 | Microcapsule-loaded stem cell system and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111803617A true CN111803617A (en) | 2020-10-23 |
Family
ID=72866533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010685869.XA Pending CN111803617A (en) | 2020-07-16 | 2020-07-16 | Microcapsule-loaded stem cell system and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111803617A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101489539A (en) * | 2006-05-10 | 2009-07-22 | 生物相容英国有限公司 | Spherical or non-spherical microcapsules comprising GLP-1 peptides, their production and use |
| CN104127884A (en) * | 2014-07-14 | 2014-11-05 | 云南省第一人民医院 | Rheumatoid arthritis treatment microcapsule and preparation method thereof |
| CN105457037A (en) * | 2014-08-18 | 2016-04-06 | 复旦大学 | Stem cell tumor targeting system with internal nano-prodrug and preparation method thereof |
| US20160137716A1 (en) * | 2013-04-12 | 2016-05-19 | Samir El Andaloussi | Therapeutic delivery vesicles |
| CN109498541A (en) * | 2018-12-12 | 2019-03-22 | 福建省海西细胞生物工程有限公司 | A kind of intelligence improves the stem cell microcapsule composition of a variety of skin problems |
| WO2019246014A1 (en) * | 2018-06-18 | 2019-12-26 | North Carolina State University | Stem cell biomimetic nanoparticle therapeutic agents and uses thereof |
-
2020
- 2020-07-16 CN CN202010685869.XA patent/CN111803617A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101489539A (en) * | 2006-05-10 | 2009-07-22 | 生物相容英国有限公司 | Spherical or non-spherical microcapsules comprising GLP-1 peptides, their production and use |
| US20160137716A1 (en) * | 2013-04-12 | 2016-05-19 | Samir El Andaloussi | Therapeutic delivery vesicles |
| CN104127884A (en) * | 2014-07-14 | 2014-11-05 | 云南省第一人民医院 | Rheumatoid arthritis treatment microcapsule and preparation method thereof |
| CN105457037A (en) * | 2014-08-18 | 2016-04-06 | 复旦大学 | Stem cell tumor targeting system with internal nano-prodrug and preparation method thereof |
| WO2019246014A1 (en) * | 2018-06-18 | 2019-12-26 | North Carolina State University | Stem cell biomimetic nanoparticle therapeutic agents and uses thereof |
| CN109498541A (en) * | 2018-12-12 | 2019-03-22 | 福建省海西细胞生物工程有限公司 | A kind of intelligence improves the stem cell microcapsule composition of a variety of skin problems |
Non-Patent Citations (3)
| Title |
|---|
| MOONHWAN CHOI等: "Therapeutic Use of Stem Cell Transplantation for Cell Replacement or Cytoprotective Effect of Microvesicle Released from Mesenchymal Stem Cell", 《MOL. CELLS》 * |
| 尤启冬等: "《2020国家执业药师职业资格考试指南 药学专业知识 1 第8版》", 31 March 2020, 中国医药科技出版社 * |
| 顾晓彤等: "细胞膜修饰的纳米粒载药系统的研究进展", 《中国医药工业杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Conover et al. | The neural stem cell niche | |
| Cheng et al. | Current progress of human trials using stem cell therapy as a treatment for diabetes mellitus | |
| Martin et al. | Energetic and morphological plasticity of C6 glioma cells grown on 3-D support; effect of transient glutamine deprivation | |
| Rodrigues et al. | Hypoxia enhances proliferation of mouse embryonic stem cell‐derived neural stem cells | |
| CN112852713A (en) | Preparation and separation method of human skin fibroblast exosome | |
| Huang et al. | Hypoxic preconditioning ameliorated neuronal injury after middle cerebral artery occlusion by promoting neurogenesis | |
| Shihabuddin et al. | Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases | |
| Ikemoto et al. | Tyrosine hydroxylase and aromatic L-amino acid decarboxylase do not coexist in neurons in the human anterior cingulate cortex | |
| CN111803617A (en) | Microcapsule-loaded stem cell system and preparation method thereof | |
| Ziavra et al. | Neural stem cells transplanted in a mouse model of Parkinson's disease differentiate to neuronal phenotypes and reduce rotational deficit | |
| Zhang et al. | Proprotein convertase 1/3-mediated down-regulation of brain-derived neurotrophic factor in cortical neurons induced by oxygen-glucose deprivation | |
| Kim et al. | Gene and cell replacement via neural stem cells | |
| WO2024066919A1 (en) | Method for differentiating stem cell into caudal serotonergic neuron, complete culture medium, and use thereof | |
| Buresh et al. | Changes in the constant potential in brain structures in rats during focal ischemia and systemic hypoxia | |
| De Lima et al. | Astroglia inhibit the proliferation of neocortical cells and prevent the generation of small GABAergic neurons in vitro | |
| Craig et al. | Plasticity in oligodendrocyte lineage progression: An OPC puzzle on our nerves | |
| CN102533653B (en) | 5-HT nerve cells induced by MSCs and ASCs and microencapsulation preparation method and application thereof | |
| Maurizi | The function of dreams (REM sleep): Roles for the hippocampus, melatonin, monoamines, and vasotocin | |
| CN111235060A (en) | Method for improving enzymatic activity of glutathione peroxidase of lactic acid bacteria | |
| CN113730372B (en) | A kind of neural stem cell phospholipid membrane microcapsule and preparation method thereof | |
| Birbrair | Recent Advances in iPSCs for Therapy | |
| CN117448271B (en) | Method for inducing differentiation of pluripotent stem cells into midbrain dopaminergic nerve precursor cells | |
| US20110250236A1 (en) | Stem cells derived from the carotid body and uses thereof | |
| Li et al. | Low glutaminase and glycolysis correlate with a high transdifferentiation efficiency in mouse cortex | |
| EP4230730A1 (en) | Chemical culture system and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201023 |